Organisation paid for research Program year 2025 Source: CMS Open Payments

Covance Laboratory

Neither a doctor nor a teaching hospital

Research payments

$619,173

11 payments

Through program year 2025, Covance Laboratory is reported as receiving $619,173 in research payments, across 11 payments.

By program year

4 rows

Year	Kind	Amount	Payments
2025	Research	$319,112	4
2024	Research	$133,699	2
2023	Research	$31,009	3
2022	Research	$135,352	2

Breakdown

Who paid Research payments · program years 2022–2025

E.R. Squibb & Sons, L.L.C. $451,114 5 payments
Celgene Corporation $168,059 6 payments

Studies the money was for Research payments · program years 2022–2025

A Phase 1, Open-label, Two-Part Study to Evaluate the Pharmacokinetics, Metabolism, and Excretion, and Absolute Bioavailability of BMS-986365 in Healthy Male Participants $302,712 1 payment
(FEDR-CP-005) BE Study - A Phase 1, Open-label, Single-center, 2-part Crossover Study to Evaluate the Relative Bioavailability of Fedratinib When Administered as Contents of Capsules Dispersed in a Nutritional Supplement Orally or Via Nasogastric Tube, or $144,799 2 payments
A Study to Evaluate the Absorption, Metabolism, and Excretion of Orally Administered [14C]-BMS-986368 in Healthy Male Participants $134,672 2 payments
Ph I Pk multitumor SubQ formulation Relatlimab $13,730 2 payments
Targeted therapy with the IDH2-inhibitor enasidenib (AG221) for high-risk IDH2-mutant MDS $9,620 1 payment
A Phase 1, Single-Center, open-label study to evaluate the metabolism and exception of [14C]-CC-90001 in healthy male subjects $8,427 1 payment
A Phase 1, Open-label, Single-center, 2-part Crossover Study to Evaluate the Relative Bioavailability of Fedratinib When Administered as Contents of Capsules Dispersed in a Nutritional Supplement Orally or Via Nasogastric Tube, or Administered Orally as Divided Doses of Intact Capsules With a Nutritional Supplement in Healthy Adult Subjects $4,000 1 payment
A Phase 1, Open-label Study to Evaluate the Effect of Fluconazole on the Pharmacokinetics of Fedratinib in Healthy Adult Subjects $1,212 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.